• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    SAB BIO Closes $85M Public Stock Offering And Pre-Funded Warrants

    GLOBENEWSWIRE

    SAB BIO Announces Common Stock and Pre-Funded Warrants Offering

    GLOBENEWSWIRE

    SAB Bio Unveils Phase 1 SAB-142 Data in Type 1 Autoimmune Disease

    GLOBENEWSWIRE

    SAB BIO Unveils 2025 Financials And Business Achievements

    GLOBENEWSWIRE

    SAB BIO To Participate In Upcoming Investor Conferences

    GLOBENEWSWIRE

    SAB BIO Strengthens Board With New Chair & Director

    GLOBENEWSWIRE

    SAB BIO To Present At J.P. Morgan Healthcare Conference

    GLOBENEWSWIRE

    First Patient Dosed In SAB Bio`s SAFEGUARD Trial For Stage 3 T1D

    GLOBENEWSWIRE

    SAB BIO Reports Positive Phase 1 Results For SAB-142 In Stage 3

    GLOBENEWSWIRE

    SAB Bio Presents SAB-142 Data at Asian Diabetes Conference

    GLOBENEWSWIRE

    SAB BIO to Present SAB-142 Data at ISPAD on Pediatric Diabetes

    GLOBENEWSWIRE

    SAB BIO Data Highlights at EASD Presentations

    GLOBENEWSWIRE

    Sab Bio to Present Five SAB-142 Studies at 2025 EASD

    GLOBENEWSWIRE

    Sab Bio Reports Q2 Financial Results, Highlights Company Updates

    GLOBENEWSWIRE

    SAB BIO Ph 1 Results Potential For Disease-Modifying T1D Therapy

    GLOBENEWSWIRE

    Sab bio Hosts Webinar On Ph 1 Results For SAB-142 In T1D Therapy

    GLOBENEWSWIRE

    SAB BIO Announces Q2 2024 Results And Company Updates

    GLOBENEWSWIRE

    SAB`s gets US FDA clearance to proceed with ph 1 trial of SAB-142

    PHARMABIZ

    FDA Clears SAB-142 Type 1 Diabetes Therapy IND

    GLOBENEWSWIRE

    SAB Announces Commencement of the HUMAN Phase 1 Trial with SAB-142

    GLOBENEWSWIRE

    SAB Bio Receives Australian Approval to Commence Phase 1 Trial of SAB-142

    GLOBENEWSWIRE

    SAB Presents Positive IND-Enabling GLP Toxicology Study for SAB-142

    GLOBENEWSWIRE

    SAB Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176

    GLOBENEWSWIRE

    SAB Bio CEO Eddie Sullivan to Present Next Generation Biologicsat Conference

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.